FDA Greenlights Pre-BLA Meeting for Rezolute's Ersodetug Despite Mixed Phase 3
RZLT has more than doubled off its 52-week low of $1.07.
Summary
FDA recommended a Type B pre-BLA meeting for ersodetug in congenital hyperinsulinism after reviewing sunRIZE data, even though the trial missed its primary and key secondary endpoints. This is a meaningful regulatory step that keeps a potential approval path alive. The company also expects upLIFT topline data for tumor HI this quarter, which could further shape the filing strategy. Cash of $107.8M from the recent 10-K provides runway through these milestones.
Updates
· SEC 8-K — The 8-K attaches the press release announcing the FDA's recommendation for a pre-BLA meeting.
At the time of this announcement, RZLT was trading at $4.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $387.9M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.